Andanda P A
University of Witwatersrand, Private Bag 3, WITS 2050, Johannesburg, South Africa.
J Med Ethics. 2008 Mar;34(3):171-9. doi: 10.1136/jme.2006.019612.
There are complex unresolved ethical, legal and social issues related to the use of human tissues obtained in the course of research or diagnostic procedures and retained for further use in research. The question of intellectual property rights over commercially viable products or procedures that are derived from these samples and the suitability or otherwise of participants relinquishing their rights to the samples needs urgent attention. The complexity of these matters lies in the fact that the relationship between intellectual property rights and ownership or rights pertaining to the samples on which the intellectual property right is based may either be overlooked or taken for granted. What equally makes the matter complex is that samples may be obtained from participants in developing countries and exported to developed countries for analysis and research. It is important for research ethics committees to tread carefully when reviewing research protocols that raise such issues for purposes of ensuring that appropriate benefit sharing agreements, particularly with developing countries, are in place. This paper attempts to analyse the key questions related to ownership and intellectual property rights in commercially viable products derived from human tissue samples. Patent law is used as a point of reference as opposed to other forms of intellectual property rights such as industrial designs because it is the right that most inventors apply for in respect of human tissue-related inventions. The key questions are formulated following a systematic analysis of peer reviewed journal articles that have reported original investigations into relevant issues in this field. Most of the cases and reported studies that are referred to in this paper do not directly deal with HIV/AIDS research but the underlying principles are helpful in HIV/AIDS research as well. Pertinent questions, which members of ethics review committees should focus on in this regard are discussed and suggestions on appropriate approaches to the issues are proposed in the form of specific questions that an ethics review committee should consider. Specific recommendations regarding areas for further research and action are equally proposed.
在研究或诊断过程中获取并留存以供后续研究使用的人体组织的使用,涉及复杂且未解决的伦理、法律和社会问题。对于从这些样本衍生出的具有商业可行性的产品或程序的知识产权问题,以及参与者放弃对样本权利的适宜性问题,都亟待关注。这些问题的复杂性在于,知识产权与作为其基础的样本的所有权或相关权利之间的关系,可能被忽视或被视为理所当然。同样使问题复杂的是,样本可能从发展中国家的参与者处获取并出口到发达国家进行分析和研究。研究伦理委员会在审查提出此类问题的研究方案时,务必谨慎行事,以确保制定适当的利益分享协议,尤其是与发展中国家的协议。本文试图分析与源自人体组织样本的具有商业可行性的产品的所有权和知识产权相关的关键问题。与其他知识产权形式(如工业设计)不同,专利法被用作参考点,因为它是大多数发明者就与人体组织相关的发明申请的权利。关键问题是在对同行评审期刊文章进行系统分析后提出的,这些文章报告了对该领域相关问题的原创性调查。本文提及的大多数案例和报告研究并非直接涉及艾滋病毒/艾滋病研究,但基本原则对艾滋病毒/艾滋病研究也有帮助。讨论了伦理审查委员会成员在这方面应关注的相关问题,并以伦理审查委员会应考虑的具体问题的形式,就处理这些问题的适当方法提出了建议。还就进一步研究和行动的领域提出了具体建议。